Destabilase-lysozyme-2 – original recombinant thrombolytic preparation of medicinal leech inhibits horse platelets aggregation.

This research investigated the effects of a novel medicinal preparation derived from leeches on the aggregation of blood platelets in horses. The researchers cloned the gene for destabilase-lysozyme in E.coli cells and analyzed its ability to prevent platelets from forming clumps.

Objective and Methodology of the Study

• The purpose of this research was to investigate the thrombolytic preparation Destabilase-Lysozyme-2, a product derived from medicinal leeches, and its capacity to inhibit blood platelet aggregation.
• The gene for destabilase-lysozyme, named ds2 (mlDL-Ds2 ), was cloned in E.coli cells. This resulted in the production of a recombinant protein.
• The recombinant protein was then isolated under denaturing conditions. This process involved metal-chelate chromatography and denaturation of the polypeptide through rapid dilution. This process adhered strictly to the procedure described in previous research by Kurdyumov A.S. et al. (2016).
• Blood was collected from the jugular vein of 18 horses for testing. The aggregation, or clumping, of platelets in the presence of different concentrations of the destabilase-lysozyme was then evaluated using specific devices called aggregometers.

Results and Conclusion of the Study

• The study found that the newly synthesized destabilase-lysozyme was able to inhibit more than 40% of ADP-stimulated platelet aggregation. This occurred in both Platelet Rich Plasma (PRP) and in washed platelets from horse blood.
• The results suggest that this new form of destabilase-lysozyme, termed destabilase-lysozyme-2, has a significant inhibitory effect on platelet aggregation. This expands the biological properties previously identified for this recombinant enzyme.
• The study has its basis in pre-clinical trials that were carried out up to the end of 2015. These trials also indicated a promising avenue of research with this recombinant thrombolytic enzyme.

Overall, this research presents a potential new avenue for the development of medical treatments to reduce blood clotting. This is of particular relevance in conditions where the prevention of clotting can be critical, such as thrombosis and cardiovascular diseases.